Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Crenigacestat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Crenigacestat overview

Crenigacestat (LY-3039478) is under development for the treatment of adenoid cystic carcinoma, soft tissue sarcoma, metastatic colon cancer, metastatic triple negative breast cancer, metastatic hepatocellular carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, leiomyosarcoma, natural killer (NK) cell neoplasm, glioblastoma, B-cell lymphoma, gastrointestinal stromal tumours (GIST), T-cell lymphoblastic lymphoma (T-LBL). The drug candidate is a new chemical entity (NCE). It is administered orally and intravenously. It targets Notch 1 receptor, and gamma-secretase. It was under development for the treatment of  T-cell acute lymphoblastic leukemia (T-ALL) and refractory/relapsed multiple myeloma.

Eli Lilly and Co overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

For a complete picture of Crenigacestat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.